Published in Int J Cancer on May 15, 1980
Stable growth transformation of human T lymphocytes by herpesvirus saimiri. Proc Natl Acad Sci U S A (1992) 2.94
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer (1982) 1.17
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology (2007) 1.16
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer (2010) 1.06
Mononuclear-cell infiltration in ovarian cancer. III. Suppressor-cell and ADCC activity of macrophages from ascitic and solid ovarian tumours. Br J Cancer (1982) 0.97
Natural cytotoxic activity in human lungs. Clin Exp Immunol (1982) 0.93
Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells. Br J Cancer (1982) 0.91
Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg (1983) 0.88
Human natural killing against ovarian carcinoma. Br J Cancer (1983) 0.83
Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells. Clin Exp Immunol (1995) 0.75
Cellular immune function study in an ovarian cancer-prone kindred. Br J Cancer (1982) 0.75
Effect of retinoids on natural killer cell activity. Arch Dermatol Res (1986) 0.75
In-vitro resistance of cloned human glioma cells to natural killer activity of allogeneic peripheral lymphocytes. Br J Cancer (1982) 0.75
The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Front Biosci (Elite Ed) (2012) 0.75
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. Br J Cancer (1983) 0.75
Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. Oncol Lett (2017) 0.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol (1987) 4.75
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 4.53
Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 4.19
Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 4.11
Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol (2000) 4.07
The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med (1998) 3.70
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 3.62
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem (1999) 3.53
Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol (1994) 3.31
IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 2.85
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84
Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol (1998) 2.70
Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A (1993) 2.67
Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today (1989) 2.60
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med (1990) 2.40
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med (1997) 2.37
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol (2001) 2.34
Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature (1989) 2.25
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation (2000) 2.19
Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol (2000) 2.17
A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol (1997) 2.15
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med (1992) 2.15
Prostacyclin synthesis induced in vascular cells by interleukin-1. Science (1985) 2.13
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10
Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol (2000) 2.10
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol (1995) 2.06
Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol (1997) 2.02
Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol (2000) 2.01
Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 2.01
Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J Immunol (1984) 2.01
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med (1997) 1.97
Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem (1997) 1.97
Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol (2001) 1.95
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 1.94
Molecular mechanisms of blood vessel formation. Trends Biochem Sci (1997) 1.93
Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol (2002) 1.93
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene (2010) 1.88
Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84
Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83
The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today (1994) 1.83
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest (1985) 1.79
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A (1994) 1.78
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res (1990) 1.77
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med (2001) 1.73
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol (1995) 1.69
Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol (2000) 1.66
Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem (1992) 1.66
Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol (1999) 1.65
Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64
Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood (1994) 1.64
Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol (1982) 1.64
Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med (1997) 1.63
IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol (1998) 1.63
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev (2000) 1.61
Intraoperative ultrasound during thoracoscopic procedures for solitary pulmonary nodules. Ann Thorac Surg (1999) 1.61
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol (1997) 1.58
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med (1998) 1.58
The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood (2000) 1.58
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.57
Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57
Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol (2001) 1.55
Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther (2010) 1.54
The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol (1999) 1.53
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol (1988) 1.53
A risk factor for female fertility and pregnancy: celiac disease. Gynecol Endocrinol (2000) 1.52
Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol (1992) 1.51